Residual Angina Following Complete Revascularization in the ISCHEMIA Trial: Frequency, Clinical Characteristics, Health Status, and Cardiovascular Outcomes
Clinical Snapshot
PICO Framework
| P — Population | Patients with chronic coronary disease, baseline angina, and anatomic complete revascularization within 90 days (n=436 from ISCHEMIA trial) |
| I — Intervention | Anatomic complete revascularization (PCI or CABG) |
| C — Comparator | Comparison between patients with and without residual angina post-revascularization |
| O — Outcomes | Primary: residual angina frequency (SAQ-AF <100 within 6 months); Secondary: health status measures, medication use, 5-year mortality |
Bottom Line
This analysis of 436 patients from the ISCHEMIA trial reveals that residual angina affects over 40% of patients despite anatomically complete revascularisation. While this doesn't increase mortality risk, it significantly impairs quality of life and physical function, requiring more antianginal medications. The finding challenges the assumption that complete anatomic revascularisation eliminates symptoms and highlights the need for comprehensive post-procedural symptom management. Clinicians should counsel patients that symptom persistence is common even after successful complete revascularisation and ensure appropriate follow-up and medical optimisation. The higher rate of residual angina in PCI versus CABG patients warrants further investigation. These findings support a patient-centred approach to revascularisation outcomes that extends beyond angiographic success to include functional and symptomatic improvement.
Key Findings
P Value: P<0.001 for quality of life and physical limitation differences
Effect Size: Quality of life difference: 13 points lower (70±20 vs 83±20) on SAQ-QOL scale
Primary Outcome: 42.2% (184/436) had residual angina within 6 months of complete revascularisation
Nnt Or Sensitivity: Number needed to harm: approximately 2.4 patients will have residual angina for every complete revascularisation
Confidence Interval: Not reported in abstract
Clinical Application
Highly feasible - uses standard revascularisation techniques and validated questionnaires available in Australian practice Relevant to Australian cardiology practice; SAQ tools available; findings support need for comprehensive post-revascularisation symptom assessment and management strategies Australian patients with chronic coronary disease undergoing complete revascularisation, particularly those with baseline angina symptoms
Abstract
BACKGROUND: The frequency of residual angina and its impact on health status and death following anatomic complete revascularization in symptomatic patients with chronic coronary disease are unknown. METHODS: Data were analyzed from ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial participants randomized to invasive management with baseline angina (Seattle Angina Questionnaire Angina Frequency score <100), no prior coronary artery bypass graft surgery, and anatomic complete revascularization within 90 days of randomization. The primary outcome was frequency of residual angina after revascularization, defined as a Seattle Angina Questionnaire Angina Frequency score <100 within 6 months of randomization. Secondary outcomes included 6-month health status and medication use and 5-year all-cause and cardiovascular death. RESULTS: Among 2588 participants randomized to invasive management, 1442 (56%) had baseline angina and no prior coronary artery bypass graft surgery; 1034 underwent revascularization within 90 days, and 436 achieved anatomic complete revascularization. Of these, 184 (42.2%) had residual angina within 6 months. Baseline characteristics were similar between those with and without residual angina. Percutaneous coronary intervention was more common than coronary artery bypass graft surgery in those with residual angina (88% versus 80%, P=0.03). At 6 months, residual angina participants reported lower quality of life (Seattle Angina Questionnaire Quality of Life: 70±20 versus 83±20, P<0.001), greater physical limitation (Seattle Angina Questionnaire Physical Limitation: 84±20 versus 95±11, P<0.001), more dyspnea (Rose Dyspnea Scale score: 1±1.3 versus 0.4±0.8, P<0.001), and more antianginal medication use (P=0.006). Five-year all-cause and cardiovascular death did not differ significantly between groups. CONCLUSIONS: Residual angina is common (>40%) following anatomic complete revascularization for chronic coronary disease and is associated with reduced quality of life and greater antianginal medication use but no increase in death. REGISTRATION: Unique Identifier: NCT01471522.
References
- 1.Singh, A., Brown, D. L., Jones, P. G., Fu, Z., Reynolds, H. R., Boden, W. E., O'Brien, S. M., Mavromatis, K., Poh, K. K., Ali, Z., Stone, G. W., Bangalore, S., Spertus, J. A., Maron, D. J., & Hochman, J. S. (2026). Residual angina following complete revascularization in the ISCHEMIA trial: Frequency, clinical characteristics, health status, and cardiovascular outcomes. Journal of the American Heart Association, Article e047355. https://doi.org/10.1161/JAHA.125.047355
Related Research
Bioelectrochemistry (Amsterdam, Netherlands)
From data to diagnosis: A comprehensive review of machine learning-driven wearable sensors in healthcare.
2 Aug 2026
Ultrasound in medicine & biology
A Systematic Review: The Application of Attention Mechanisms in Medical Ultrasound Image Processing
2 Aug 2026
Journal of the American Medical Informatics Association : JAMIA
Explainable machine learning in healthcare: methods, interpretation, and applications for clinical research
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service